
Sign up to save your podcasts
Or
For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/RMQ865. CME/AAPA credit will be available until April 3, 2026.
Time-Limited Innovation for CLL Control: Changing the Treatment Story With Evidence and Emerging Consensus on 1L BTKi -BCL2i Combinations
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Support
This activity is supported by an educational grant from Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
Disclosure information is available at the beginning of the video presentation.
4.6
99 ratings
For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/RMQ865. CME/AAPA credit will be available until April 3, 2026.
Time-Limited Innovation for CLL Control: Changing the Treatment Story With Evidence and Emerging Consensus on 1L BTKi -BCL2i Combinations
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Support
This activity is supported by an educational grant from Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
Disclosure information is available at the beginning of the video presentation.
127 Listeners
6 Listeners
3 Listeners
3 Listeners
11 Listeners
5 Listeners
28 Listeners
10 Listeners
3 Listeners
2 Listeners
4 Listeners
3 Listeners
131 Listeners
3 Listeners
5 Listeners
5 Listeners
2 Listeners
0 Listeners
315 Listeners
2 Listeners
96 Listeners
13 Listeners
275 Listeners
2 Listeners
688 Listeners
3,321 Listeners
91 Listeners
1,085 Listeners
175 Listeners
281 Listeners
513 Listeners
48 Listeners
8,716 Listeners